Literature DB >> 22998096

Statin drugs: reducing cardiovascular risk in older adults.

Kellie McLain1, Barbara J Edlund.   

Abstract

Dyslipidemia is one of the most modifiable risk factors in preventing heart disease. Evidence demonstrates that the process of atherosclerosis, a result of dyslipidemia, begins in young adults. Initiating statin therapy has been shown to reduce the risk of cardiovascular events and mortality. Determining the right statin medication and dose for an older adult based on national guidelines can be challenging, as multiple factors must be considered in this decision. When initiating statin therapy, clinicians should determine the appropriate percentage of reduction in low-density lipoprotein cholesterol needed to achieve the target goal. Additionally, when changing from one cholesterol-lowering medication to another, knowledge of equivalent dosing is important. Generally, statin drugs are well tolerated with a good safety profile in older adults but are underused in this patient population. Issues such as existing comorbid conditions, polypharmacy with the potential for drug-drug interactions, impaired drug metabolism, and decreased functional status can contribute to adverse events and increase the frequency of myalgias and less frequently, hepatotoxicity. Clinicians prescribing statin therapy for older adults need to remain current on advances in research regarding potential interactions and contraindications within this drug class. Copyright 2012, SLACK Incorporated.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22998096     DOI: 10.3928/00989134-20120911-04

Source DB:  PubMed          Journal:  J Gerontol Nurs        ISSN: 0098-9134            Impact factor:   1.254


  1 in total

1.  PPARgamma-2 and ADRB3 polymorphisms in connective tissue diseases and lipid disorders.

Authors:  Bogna Grygiel-Górniak; Iwona Ziółkowska-Suchanek; Elżbieta Kaczmarek; Maria Mosor; Jerzy Nowak; Mariusz Puszczewicz
Journal:  Clin Interv Aging       Date:  2018-03-22       Impact factor: 4.458

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.